You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII)

Article Text

Article menu

Download PDFPDF

Poster Presentation
Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII)
  1. Anthony K Park1,
  2. Saul Priceman1,
  3. Ethan Gerdts1,
  4. Wen-Chung Chang1,
  5. Sarah Wright1,
  6. Stephen J Forman2 and
  7. Christine E Brown2
  1. Aff1 grid.410425.60000000404218357City of Hope National Medical Center Duarte CA USA
  2. Aff2 grid.410425.60000000404218357Beckman Research Institute, City of Hope National Medical Center Duarte CA USA

https://doi.org/10.1186/2051-1426-3-S2-P119

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Glioblastoma multiforme (GBM) is the most common brain tumor, with a poor prognosis of less than 14 months after initial diagnosis. Gene amplification and mutation of epidermal growth factor receptor (EGFR) are frequently observed in primary GBM. The most common variant of EGFR, known as EGFRvIII, is expressed in approximately 30% of GBM patients, but is absent on normal cells, making it a desirable target for cancer immunotherapy. In addition to the surge of adoptive cell immunotherapies for the treatment of advanced cancers, chimeric antigen receptors (CARs) have come to the forefront as a promising therapeutic strategy. We have engineered genetically modified T cells to express CARs that specifically target tumor cells expressing EGFRvIII and/or amplified EGFR for the treatment of malignant gliomas.

    Our studies have focused on optimizing the EGFRvIII-CAR structural design, including the antigen-targeting domain (scFv), extracellular non-signaling linker, and intracellular co-stimulatory signaling domains, to improve overall CAR T cell specificity and efficacy. Thus, we have compared five different scFvs for targeting EGFRvIII, and four different linkers with varying lengths. CAR activity was evaluated using a variety of in vitro functional assays, including CD107a degranulation, IFN-γ production, PD-1 induction, T cell proliferation and tumor killing assays. Using these assays, we have defined CARs capable of mediating highly-specific activation and killing of target tumor cells expressing EGFRvIII and/or amplified EGFR, with minimal targeting of endogenous EGFR-expressing cells. We further validated our EGFRvIII-specific CAR T cells using preclinical human xenograft models of GBM. Our in vivo tumor studies show dose-dependent killing by locally administered EGFRvIII-CAR T cells against subcutaneous tumors expressing EGFRvIII. Combined, these studies demonstrate potent anti-tumor activity of EGFRvIII-specific CAR T cells.